NCT01647568

Safety of Continuing Anti-platelet Agents During Colonoscopic Polypectomy: A Prospective Study

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 715 (actual)
• Sponsor: Dallas VA Medical Center · Federal
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

At our VA hospital, in general, it is the policy of our GI lab to not stop our patients anti-platelet therapy whenever they see us for a routine colonoscopy. We do this because we believe the risk of stopping these sort of medications outweigh the risks of a complication from a colonoscopy. Therefore, we are enrolling patients who are either on clopidogrel or prasugrel or not on any anti-platelet/anti-coagulant therapy that come to our GI lab routine colonoscopies. We perform the procedure just like we normally would and then follow-up with the patient 7 and 30 days after their procedure.

Conditions

• Post-polypectomy Bleeding
• Anti-platelet Therapy
• Colonoscopy

Timeline

• Start date: 2009-12-01
• Primary completion: 2012-03-01
• First posted: 2012-07-23
• Last updated: 2012-07-23

Locations

1 site across 1 country: United States